Supplementary Table 2.

Clinical Characteristics of Patients Used for Biopsy Cultures

Sample	Patient	Age	Gender	CD/UC	Disease extent UC/Montreal	CRP	Endoscopic evidence active disease	Medications
cf01	1	44	M	CD	A1L1L4B2	13	Yes	Thiopurine and steroids
cf02	2	20	F	CD	A1L2L4B1	6	Yes	Adalimumab and thiopurine
cf03	3	41	F	CD	A2L2B1p		No	None
cf04	4	25	M	CD	A2L2B1p	<5	Yes	Thiopurine and steroids
cf05	5	55	M	CD	A2L3B1P	<5	Yes	Thiopurine
cf06	6	59	F	UC	E2	<5	Yes	Steroids
cf07	7	59	F	UC	E1	<5	No	None
cf08	8	58	M	UC	E3	<5	Yes	None
cf09	9	68	M	UC	E3	<5	No	None
cf10	10	41	M	UC	E3	<5	Yes	None
cf11	11	35	M	UC	E2	19	Yes	None
cf12	12	37	M	CD	A1L3B2	<5	Yes	None
cf13	13	17	F	CD	A1L3B2	<5	Yes	Thiopurine
cf14	14	40	F	UC	E3	<5	Yes	None
cf15	15	39	F	UC	E3	<5	No	None
cf16	16	21	M	UC	E3	<5	No	Thiopurine and steroids
cf17	17	21	M	UC	E3	<5	Yes	Methotrexate and steroids
cf21	18	50	F	UC	E2	<5	Yes	None
cf23	19	41	M	UC	E3	<5	Yes	Thiopurine
cf24	20	51	F	UC	E1	<5	Yes	None
cf25	21	20	M	CD		16	Yes	Infliximab
cf26	22	21	M	UC	E3	<5	No	None
cf28	23	27	F	CD	A2L3B2p	<5	No	Steroids
cf32	24	59	M	CD	A3L2B1	<5	No	None
cf33	25	40	F	UC	E3	<5	No	None
cf34	26	29	M	CD	A2L1	<5	Yes	Methotrexate
cf36	27	46	F	CD	A1L3B2	7	Yes	None
cf37	28	46	F	CD	A1L3B2	7	Yes	None
cf38	29	43	F	CD	A2L3B2p	<5	Yes	Adalimumab and methotrexate

CD, Crohn’s disease; CRP, C-reactive protein; UC, ulcerative colitis.